Several weeks earlier, in announcing an acquisition of the clinical-stage radiopharmaceutical contract development and manufacturing organization Evergreen Theragnostics, Massachusetts-based Lantheus ...

CDMO( Radio pharma)- Quality Assurance Specialist at Evergreen Theragnostics a Lantheus Company ...

Lantheus is promising up to $1.8 billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales.

Mary Anne Heino, a director at Lantheus Holdings, Inc. (NASDAQ:LNTH), a $6.89 billion medical diagnostics company with an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tumours (NETs).

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

**NM signifies a non meaningful value. A dash signifies the data is not available.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Real time quote data is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.